Overview

An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Treatments:
Lifitegrast
Ophthalmic Solutions
Pharmaceutical Solutions